Abstract:DNA damage response and repair (DDR) gene alterations increase tumor-infiltrating lymphocytes, genomic instability, and tumor mutational burden (TMB). Whether DDR-related alterations relate to therapeutic response and prognosis in lung cancer lacking oncogenic drivers remains unknown. Pretherapeutic cancer samples of 122 patients [86 non-small cell lung cancer and 36 small cell lung cancer (SCLC)] harboring no EGFR/ALK alterations were collected. Through whole-exome sequencing, we outlined DDR mutational landscape and determined relationships between DDR gene alterations and TMB or intratumoral heterogeneity. Then, we evaluated the impacts of DDR gene alterations on therapeutic response and prognosis and established a DDR-based model for prognosis prediction. In addition, we investigated somatic interactions of DDR genes and immunomodulatory genes, immune expression patterns, immune microenvironment, and immune infiltration characteristics between DDR-deficient and DDR-proficient samples. Samples from cBioportal datasets were utilized for verification. We found that deleterious DDR gene alterations were closely associated with higher TMB than proficient-types ( p < 0.001). DDR mechanisms attach great importance to the determination of patients’ prognosis after chemotherapy, and alterations of base excision repair pathway in adenocarcinoma, nucleotide excision repair in squamous carcinoma, and homologous recombination pathway in SCLC tend to associate with worse progression-free survival to first-line chemotherapy (all p < 0.05). A predictive nomogram model was constructed incorporating DDR-related alterations, clinical stage, and smoking status, with the area under curve values of 0.692–0.789 for 1- and 2-year receiver operating characteristic curves in training and testing cohorts. Furthermore, DDR-altered tumors contained enhanced frequencies of alterations in various genes of human leukocyte antigen (HLA) class I pathway including TAP1 and TAP2 than DDR-proficient samples. DDR-deficient types had lower expressions of STING1 ( p = 0.01), CD28 ( p = 0.020), HLA-DRB6 ( p = 0.014) in adenocarcinoma, lower TNFRSF4 ( p = 0.017), and TGFB1 expressions ( p = 0.033) in squamous carcinoma, and higher CD40 ( p = 0.012) and TNFRSF14 expressions (p = 0.022) in SCLC. DDR alteration enhanced activated mast cells in adenocarcinoma ( p = 0.044) and M2 macrophage in squamous carcinoma ( p = 0.004) than DDR-proficient types. Collectively, DDR gene alterations in lung cancer without oncogenic drivers are positively associated with high TMB. Specific DDR gene alterations tend to associate with worse progression-free survival to initial chemotherapy.

Targeting DNA Damage Response Deficiency in Thoracic Cancers

Targeting DNA damage response pathways in cancer

Targeting the DNA damage response in hematological malignancies

DNA damage response defects in hematologic malignancies: mechanistic insights and therapeutic strategies

The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer

DNA Damage Response and Repair Gene Alterations Increase Tumor Mutational Burden and Promote Poor Prognosis of Advanced Lung Cancer

DNA damage response in breast cancer and its significant role in guiding novel precise therapies

Advancing cancer therapy: new frontiers in targeting DNA damage response

Targeting DNA damage response deficiency in the treatment of breast cancer

Abstract MS1-3: Targeting DNA damage response and HRD in breast cancer

Replication Fork Remodeling and Therapy Escape in DNA Damage Response-Deficient Cancers

Recent Progress in DNA Damage Response-Targeting PROTAC Degraders

Abstract IA010: Latest developments in targeting the DNA damage response in the clinic

DNA damage response and repair gene mutations are associated with tumor mutational burden and outcomes to platinum-based chemotherapy/immunotherapy in advanced NSCLC patients

Targeting DNA damage response as a potential therapeutic strategy for head and neck squamous cell carcinoma

A novel DNA damage repair-related signature for predicting prognositc and treatment response in non-small lung cancer

DNA Damage Response Inhibitors: an Avenue for TNBC Treatment

Therapeutic Targeting of DNA Repair Pathways in Pediatric Extracranial Solid Tumors: Current State and Implications for Immunotherapy

Targeting DNA damage response in pancreatic ductal adenocarcinoma: A review of preclinical and clinical evidence

Recent Advances in Cancer Therapy Targeting Proteins Involved in DNA Double-Strand Break Repair

DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications